Due to the big role EGFR plays in GBM proliferation and growth, and its very common overexpression and amplification in large amounts of patients, it is a frequent target for cancer therapies, especially for modern tyrosine kinase inhibitors [90,93]. Here, EGFR is linked to glioblastoma.